EMA Updates Brexit Guidance
On Dec. 1, 2017, the European Medicines Agency (EMA) and the European Commission published updated guidance for pharmaceutical companies regarding the United Kingdom’s withdrawal from the European Union. The new guidance answers additional questions about marketing applications and authorizations.
New in this update is more information on batch release sites located in the UK, which must be located in the EU; the effect on herbal medicinal products; and applications for orphan drug designation. The guidance also discusses the local representatives in the UK mentioned in product information, global marketing, and the sunset clause.
Source: EMA
|
|---|
|
Columnists
Webcasts
Outsourcing
Fifteen Years of Progress: Biopharmaceutical Industry Survey Results
This article highlights 15 years of changes in biopharmaceutical manufacturing.
Catalent to Acquire Juniper Pharmaceuticals
Catalent’s acquisition of Juniper Pharmaceuticals further expands its early development capabilities.
Alcami Expands Laboratory Services Program
The company expanded its extended workbench laboratory services program to support the ongoing manufacturing and development of Flexion Therapeutics’s Zilretta (triamcinolone acetonide extended-release injectable suspension).
Sponsored Links
